Teva’s Copaxone Suit Is “Absolutely Unprecedented,” FDA Says
FDA says Teva’s argument to court about dire impact of potential glatiramer ANDAs does not match its statements to investors.
FDA says Teva’s argument to court about dire impact of potential glatiramer ANDAs does not match its statements to investors.